| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO and Director | CEO and Executive Chairman
2 companies
Mendlein John is a Director at ATYR, with reported holdings spanning 2 companies. Recent filings cover 11 purchases and 3 sales. Those positions are worth an estimated $687K at current prices.
Our model assigns Mendlein John a middling insider score of 50/100, based on 4 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of +31.5%.
Mendlein John's largest disclosed position is in FATE as Director, worth about $426K. Net of sales, the recent Form 4 record there shows accumulation of 91,753 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 13, 2023 | FATE Fate Therapeutics Inc | Director | Buy | 124,679 | $5.60 | $698,138.49 | +78.9% | +14.8% | -15.7% | |
| Jun 3, 2022 | FATE Fate Therapeutics Inc | Director | Sell | 1,364 | $22.79 | $31,085.56 | -0.9% | +14.3% | -77.8% | |
| Mar 10, 2022 | FATE Fate Therapeutics Inc | Director | Sale+OE | 31,562 | $35.02 | $1,105,200.01 | -16.5% | -31.6% | -86.2% | |
| Dec 21, 2018 | ATYR Atyr Pharma Inc | Director | Buy | 245,000 | $0.42 | $103,247.00 | +66.1% | - | - | |
| Aug 31, 2017 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 37,736 | $2.65 | $100,000.40 | +11.4% | - | - | |
| Apr 24, 2017 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 124 | $3.00 | $372.00 | - | - | - | |
| Apr 20, 2017 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 2,552 | $3.00 | $7,656.00 | +0.8% | - | - | |
| Dec 19, 2016 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 69,000 | $2.20 | $151,662.00 | +27.0% | - | - | |
| Apr 5, 2016 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 2,500 | $3.52 | $8,800.00 | +1.0% | - | - | |
| Apr 5, 2016 | ATYR Atyr Pharma Inc | CEO and Director | Buy | 2,500 | $3.55 | $8,875.00 | +1.0% | - | - |